Financing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation

Similar documents
COURSE ON VENTURE CAPITAL AND ITS ROLE IN THE FUNDING OF START-UP COMPANIES

Start-up Ecosystem Investor Selection Screening Female Founder Summit 2017

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment

Overview of Venture Equity

Financing Emerging Growth Companies

Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiatin

Private Equity Market and Trends Brigitte Baumann CEO Go Beyond; President of EBAN

Raising Capital. Get the Money You Need to Grow Your Business. Third Edition. Andrew J. Sherman

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

How to Attract Venture Capital

IDEO PROJECT. Venture Capital & Private Equity LATVIA

Give Me 5: GENDER LENS INVESTING: THE RISING TIDE OF WOMEN ANGELS

Preparing for and Raising Early Stage Capital in Maine

Private Equity and Venture Capital in Switzerland

Transaction Services. Member of Invest Europe and SECA Swiss Priva te E quity & Corporate Finance Association

SESSION 9A: SOURCES OF CAPITAL, VC FUND ECONOMICS

Commercialization Strategies that Work

Industrial Technologies. Amsterdam, June 2016 Nitan Pathak European Investment Fund

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

VENTURE CAPITAL USAGE AND ITS STAGES

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

Mario M. Casabona Founder and General Partner Casabona Ventures, LLC Early Stage Technology Company Funding

Session 14 Venture Finance

SESSION 4: Mr. Hanson Cheah, Managing Partner, AsiaTech Ventures Limited, Hong Kong

Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc.

Forum Science & Business FCRi - EY Foundation

Mergers and Acquisitions/ Private Equity. Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors. Attorney Advertising

Angel Investor Networks The Power of Groups

2Q 2017 Results. 11 Aug 2017 MERMAID MARITIME PUBLIC COMPANY LIMITED

ITRE Committee European Parliament Hearing on Horizon Chiara de Caro, EBAN General Manager March 20 th 2012

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

E Profesor Tom Byers

Professor Randy Komisar Stanford University

About Us. Sterling Capital is a China centric boutique M&A firm with extensive on the ground China experience since 2003.

The Danish-American Entrepreneurship Summit

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

VENTURE CAPITAL. Financing startup and emerging growth companies Long term/patient capital Equity financing High Risk/High Return Exits: M &A or IPO

Managing Risk in my career and investing in start-ups

Entrepreneurship WILEY. Third Edition. William D. Bygrave. Andrew Zacharakis. Babson College. Babson College

Venture Capital Report

WPI Intellectual Property A day in the life of the tech transfer office. Todd Keiller Director, Intellectual Property and Innovation

International Women s Day Celebrates Entrepreneurs. How to be a Money Magnet

a viable alternative to Venture Capital?

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Drivers of Innovation in the US High Tech Model

PRESENTATION ON PRIVATE EQUITY 16 th January, 2017 at the Institute of Chartered Accountants of India, EIRC

Private Equity & Management Buy-Outs This course is presented in London on: 25 January 2018, 18 May 2018, 25 October 2018

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.

Intellectual Ventures

Israel Venture Capital Investments Report Q3 2017

VENTURE CAPITAL IN THE UNITED STATES

Debt & Equity A Match Made in Heaven? The Investor s Perspective. Colin Walsh

Best practice case study

TECH START-UP CONNECTING ACROSS GEOGRAPHIES

San Diego Startup Week (SDSW) STARTUP WEEK. is the region s premier catalyst for innovation, creativity & entrepreneurialism.

CDP-EIF ITAtech Equity Platform

OECD/ADBI 7th Round Table on Capital Market Reform in Asia October 2005 ADB Institute, Tokyo, Japan

IEEE Boston Entrepreneurs Network. Raising Money from VCs. April 2012

HOTELS, TOURISM & LEISURE. Hotels, Tourism & Leisure

Venture Debt in CEE. Venture Debt Summit 2018 March 22, Luxembourg

15.431: Entrepreneurial Finance

Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Private Equity & Management Buy-Outs

Angel Financing. UNCP Entrepreneurial Summit UNCP Regional Center at COMtech Pembroke, NC 12 March Presented by:

things that I learned from my startup experience PART 5 Funding Suhas Dutta

EQUITY STRUCTURES FOR HIGH GROWTH ENTREPRENEURIAL VENTURES

Financing Innovation. Dr. Harald Nieder. Université de Neuchâtel, 18 Feb Copyright Redalpine Venture Partners AG, Switzerland

Raising Capital: Practical Tips for Entrepreneurs

THE NEXT DATE. Angelos Manglis. 17 th Infocom World How to raise money from VCs, BAs. Founder of Atlantis Consulting S.A.

ECSEL JU Symposium 2018 Electronics: a vision and how to get there Lessons learned from study on access-to-finance conditions. Brussels, June

Funding & Patents. Enterprise & Project Management

Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Venture Capital Industry Overview. Powered By:

SMEs. Access to finance for. Screening Process with Serbia - Chapter 20. SME Access to Finance Directorate-General for Enterprise and Industry

FINDING THE MONEY Fundraising for Early Stage Capital

Moore Thompson: the corporate finance experts

Wineus AG. Company presentation 2016

Master Class : Excellence in Private Equity & Deal Structuring

The Future of Growth and the Energy Industry

Capital Partners Advisers & Capital Partners Securities Investment Banking Division of Capital Partners Group

Financing Entrepreneurship: Is Gender an Issue?

Thelander 2016 PRIVATE COMPANY YEAR END MERIT INCREASE PITCHBOOK REPORT. J. Thelander Consulting

ESban Financing Innovation in SMEs: the role of Business Angels 11 th December 2009, Madrid

Preparing For and Surviving an M&A Transaction

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics

An Experienced Approach to Private Equity

Applied Investment Management Open House September 8, Investment Banking / Private Equity Track

Contents. 1 Introduction... 1

Founder Follies. Presentation for Harvard Business School. February 9, Jeffrey L. Quillen Alexander J. Aber

The Case for Scaling Corporate Venture Investment. in Tech in Europe. Findings & Insights by. 26 April 2017

What Do You Do When Your Board of Directors Wants to Monetize Your Intellectual Property Assets?

Venture Capital For Dummies Free Ebooks PDF

executives are often viewed to better understand the merits of scientific over commercial solutions.

W H AT W E D O SPONSORS. Contents INVESTMENT TERMS SENIOR MANAGEMENT

Crafting Powerful Business Solutions

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Landis+Gyr - a PE driven business transformation and successful buyout

GLOBAL & LOCAL INVESTMENT TRENDS

小心站台空隙. Don Merino Vice President and General Manager, Asia Licensing Sales. December 2, 2011

The role of Intellectual Property (IP) in R&D-based companies: Setting the context of the relative importance and Management of IP

Transcription:

30.04.2014 Aitana Peire Venture Valuation

Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Information services / Life Sciences Databases Biotechgate: www.biotechgate.com Offices Employees Clients HQ: Zurich with representative offices in North America, Europe and Asia (Singapore, Seoul) 5 people in Switzerland, 8 representatives, JV in India Pharma, Biotech and Investors such as Novartis Venture Fund, GSK, European Investment Bank, 4SC, Arpida/Evolva, Celtic Pharma

Agenda Financing Sources VC process / Dos and Don ts in raising money Conclusion A couple of sources

Agenda Financing Sources VC process / Dos and Don ts in raising money Conclusion A couple of sources

Financing Sources Out-licensing Value retention; lead vs follow-on products Own development resources needed Own financing Services Grants/ Government funding Raise capital Equity: VC, Corporate, Family Office, Business Angels Venture Debt/ Convertibles Debt Product Financing

Financing Sources Earlier Stage products (products 3, 4, 5) Lead Products (products 1&2) Equity Financing (-) Fund raised on later stage products Price: low/ none within portfolio (++) Preserve potential within company Creates main value for investors Licensing Deal (++) Interesting for pharma Limited value to VC/ analyst (+) Reduces burn-rate Provides Cash Depending on deal terms/ value

Agenda Financing Sources VC process / Dos and Don ts in raising money Conclusion A couple of sources

VC Process Deal flow Initial screening Due Diligence / Assessment Valuation Monitoring Exit Negotiation Access to projects Decision making and negotiations Reporting and support Divesting and generating return

VC Process Investors look for exit possibilities to realize return Sales of shares very difficult An exit via different channels ipossible Merger & Acquisition (M&A) Management Buy-out (MBO) Initial Public Offering (IPO)

Dos for the preparation Be specific. Substantiate statements with market data Summarize and properly structure financial information; review by outside parties Show how much money you need; how do you spend it Attractive business plan (design), but not overdone Network like crazy Choosing your VC is as choosing a co-founder Do reference checks on the VC (previous investments) Having multiple term sheets makes a difference.

Don ts for the preparation Don t use highly technical descriptions of products Don t make vague or unsubstantiated statements Don't ignore or underplay your competition Don't ignore key risks Don t take the funding process lightly Don t try to raise between significant milestones Don't be afraid to ask for adequate funding

Dos in Sales pitch Show a clear and logical exit strategy Save up good news for the middle of the process Wait until you have significant traction Be direct and have a plan VCs like to see your confidence Be open and honest Be brief provide executive summary Cite clearly how much money the company will need Be realistic in making estimates and assessing market

Dont s in Sales pitch Don t pitch ideal VCs first practice Don t just pitch - listen to the VC Don t be defensive Don t pick your investor solely on brand/name. Don t plan on closing any rounds in August / December or within a short time Don t engage in a bidding war. Don t travel too much stay local Don t press people beyond the Thank You email after a meeting.

Agenda Financing Sources VC process / Dos and Don ts in raising money Conclusion A couple of sources

Conclusion Think outside the box / options Use local government and global research grants (nondilutive) Find best match for own development Consider licensing (in- and out-licensing) Understand the value of each product Get the money when you can Network, network, network

Agenda Financing Sources VC process / Dos and Don ts in raising money Conclusion A couple of sources

A couple of sources European Private Equity and Venture Capital Association http://www.evca.eu/

A couple of sources The Swiss Private Equity & Corporate Finance Association http://www.seca.ch/templates/templates/vc-model-documentation.aspx

Thank you! Aitana Peire Venture Valuation a.peire@venturevaluation.com

Financing Sources Equity Finance Venture Capital Corporate Investors Family Offices Business Angels Size > EUR 3.5m Open Open < USD 1.5m Company type Total capital requirement High risk / potential Exit Set 5-10 years Strategic fit, innovative Service component, opportunistic High High Medium Low M&A Long-term partner Seed / early stage Medium term

Financing Sources Non-equity Finance Debt Financing Grant / Government Convertibles Revenue, Royalty Product Financing Size open < EUR 3.5m open > EUR 7m Company type Total capital requirement Mature companies Innovative, R&D, early stage High growth, later stage High All All High Exit Repayment None Repay / convert Mature, later stage none